Loading
A phase 3 trial of Dostarlimab and Pembrolizumab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06472076 by GlaxoSmithKline, with 88 participants enrolled, started 2024-06-10 and due to reach its primary completion in 2026-06-30. Interventions recorded: Dostarlimab, Belrestotug, Pembrolizumab and Placebo.
Shares Dostarlimab, GSK, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.